High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: A 1H MRS study

Wei Huang, Gene E. Alexander, Eileen M. Daly, H. Umesha Shetty, Jack S. Krasuski, Stanley I. Rapoport, Mark B. Schapiro

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Objective: An extra portion of chromosome 21 in Down's syndrome leads to a dementia in later life that is phenotypically similar to Alzheimer's disease. Down's syndrome therefore represents a model for studying preclinical stages of Alzheimer's disease. Markers that have been investigated in symptomatic Alzheimer's disease are myo-inositol and N- acetylaspartate. The authors investigated whether abnormal brain levels of myo-inositol and other metabolites occur in the preclinical stages of Alzheimer's disease associated with Down's syndrome. Method: The authors used 1H magnetic resonance spectroscopy (MRS) with external standards to measure absolute brain metabolite concentrations in 19 nondemented adults with Down's syndrome and 17 age- and sex-matched healthy comparison subjects. Results: Concentrations of myo-inositol and choline-containing compounds were significantly higher in the occipital and parietal regions of the adults with Down's syndrome than in the comparison subjects. Within the Down's syndrome group, older subjects (42-62 years, N=11) had higher myo-inositol levels than younger subjects (28-39 years, N=8). Older subjects in both groups had lower N-acetylaspartate levels than the respective younger subjects, although this old-young difference was not greater in the Down's syndrome group. Conclusions: The approximately 50% higher level of myo-inositol in Down's syndrome suggests a gene dose effect of the extra chromosome 21, where the human osmoregulatory sodium/myo-inositol cotransporter gene is located. The even higher myoinositol level in older adults with Down's syndrome extends to the predementia phase earlier findings of high myo-inositol levels in symptomatic Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)1879-1886
Number of pages8
JournalAmerican Journal of Psychiatry
Volume156
Issue number12
StatePublished - Dec 1999
Externally publishedYes

Fingerprint

Inositol
Down Syndrome
Alzheimer Disease
Magnetic Resonance Spectroscopy
Brain
Chromosomes, Human, Pair 21
Occipital Lobe
Parietal Lobe
Choline
Genes
Dementia
Healthy Volunteers

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Huang, W., Alexander, G. E., Daly, E. M., Shetty, H. U., Krasuski, J. S., Rapoport, S. I., & Schapiro, M. B. (1999). High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: A 1H MRS study. American Journal of Psychiatry, 156(12), 1879-1886.

High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome : A 1H MRS study. / Huang, Wei; Alexander, Gene E.; Daly, Eileen M.; Shetty, H. Umesha; Krasuski, Jack S.; Rapoport, Stanley I.; Schapiro, Mark B.

In: American Journal of Psychiatry, Vol. 156, No. 12, 12.1999, p. 1879-1886.

Research output: Contribution to journalArticle

Huang, W, Alexander, GE, Daly, EM, Shetty, HU, Krasuski, JS, Rapoport, SI & Schapiro, MB 1999, 'High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: A 1H MRS study', American Journal of Psychiatry, vol. 156, no. 12, pp. 1879-1886.
Huang, Wei ; Alexander, Gene E. ; Daly, Eileen M. ; Shetty, H. Umesha ; Krasuski, Jack S. ; Rapoport, Stanley I. ; Schapiro, Mark B. / High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome : A 1H MRS study. In: American Journal of Psychiatry. 1999 ; Vol. 156, No. 12. pp. 1879-1886.
@article{6bc25a42374c4a978f670d5922101abf,
title = "High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: A 1H MRS study",
abstract = "Objective: An extra portion of chromosome 21 in Down's syndrome leads to a dementia in later life that is phenotypically similar to Alzheimer's disease. Down's syndrome therefore represents a model for studying preclinical stages of Alzheimer's disease. Markers that have been investigated in symptomatic Alzheimer's disease are myo-inositol and N- acetylaspartate. The authors investigated whether abnormal brain levels of myo-inositol and other metabolites occur in the preclinical stages of Alzheimer's disease associated with Down's syndrome. Method: The authors used 1H magnetic resonance spectroscopy (MRS) with external standards to measure absolute brain metabolite concentrations in 19 nondemented adults with Down's syndrome and 17 age- and sex-matched healthy comparison subjects. Results: Concentrations of myo-inositol and choline-containing compounds were significantly higher in the occipital and parietal regions of the adults with Down's syndrome than in the comparison subjects. Within the Down's syndrome group, older subjects (42-62 years, N=11) had higher myo-inositol levels than younger subjects (28-39 years, N=8). Older subjects in both groups had lower N-acetylaspartate levels than the respective younger subjects, although this old-young difference was not greater in the Down's syndrome group. Conclusions: The approximately 50{\%} higher level of myo-inositol in Down's syndrome suggests a gene dose effect of the extra chromosome 21, where the human osmoregulatory sodium/myo-inositol cotransporter gene is located. The even higher myoinositol level in older adults with Down's syndrome extends to the predementia phase earlier findings of high myo-inositol levels in symptomatic Alzheimer's disease.",
author = "Wei Huang and Alexander, {Gene E.} and Daly, {Eileen M.} and Shetty, {H. Umesha} and Krasuski, {Jack S.} and Rapoport, {Stanley I.} and Schapiro, {Mark B.}",
year = "1999",
month = "12",
language = "English (US)",
volume = "156",
pages = "1879--1886",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "12",

}

TY - JOUR

T1 - High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome

T2 - A 1H MRS study

AU - Huang, Wei

AU - Alexander, Gene E.

AU - Daly, Eileen M.

AU - Shetty, H. Umesha

AU - Krasuski, Jack S.

AU - Rapoport, Stanley I.

AU - Schapiro, Mark B.

PY - 1999/12

Y1 - 1999/12

N2 - Objective: An extra portion of chromosome 21 in Down's syndrome leads to a dementia in later life that is phenotypically similar to Alzheimer's disease. Down's syndrome therefore represents a model for studying preclinical stages of Alzheimer's disease. Markers that have been investigated in symptomatic Alzheimer's disease are myo-inositol and N- acetylaspartate. The authors investigated whether abnormal brain levels of myo-inositol and other metabolites occur in the preclinical stages of Alzheimer's disease associated with Down's syndrome. Method: The authors used 1H magnetic resonance spectroscopy (MRS) with external standards to measure absolute brain metabolite concentrations in 19 nondemented adults with Down's syndrome and 17 age- and sex-matched healthy comparison subjects. Results: Concentrations of myo-inositol and choline-containing compounds were significantly higher in the occipital and parietal regions of the adults with Down's syndrome than in the comparison subjects. Within the Down's syndrome group, older subjects (42-62 years, N=11) had higher myo-inositol levels than younger subjects (28-39 years, N=8). Older subjects in both groups had lower N-acetylaspartate levels than the respective younger subjects, although this old-young difference was not greater in the Down's syndrome group. Conclusions: The approximately 50% higher level of myo-inositol in Down's syndrome suggests a gene dose effect of the extra chromosome 21, where the human osmoregulatory sodium/myo-inositol cotransporter gene is located. The even higher myoinositol level in older adults with Down's syndrome extends to the predementia phase earlier findings of high myo-inositol levels in symptomatic Alzheimer's disease.

AB - Objective: An extra portion of chromosome 21 in Down's syndrome leads to a dementia in later life that is phenotypically similar to Alzheimer's disease. Down's syndrome therefore represents a model for studying preclinical stages of Alzheimer's disease. Markers that have been investigated in symptomatic Alzheimer's disease are myo-inositol and N- acetylaspartate. The authors investigated whether abnormal brain levels of myo-inositol and other metabolites occur in the preclinical stages of Alzheimer's disease associated with Down's syndrome. Method: The authors used 1H magnetic resonance spectroscopy (MRS) with external standards to measure absolute brain metabolite concentrations in 19 nondemented adults with Down's syndrome and 17 age- and sex-matched healthy comparison subjects. Results: Concentrations of myo-inositol and choline-containing compounds were significantly higher in the occipital and parietal regions of the adults with Down's syndrome than in the comparison subjects. Within the Down's syndrome group, older subjects (42-62 years, N=11) had higher myo-inositol levels than younger subjects (28-39 years, N=8). Older subjects in both groups had lower N-acetylaspartate levels than the respective younger subjects, although this old-young difference was not greater in the Down's syndrome group. Conclusions: The approximately 50% higher level of myo-inositol in Down's syndrome suggests a gene dose effect of the extra chromosome 21, where the human osmoregulatory sodium/myo-inositol cotransporter gene is located. The even higher myoinositol level in older adults with Down's syndrome extends to the predementia phase earlier findings of high myo-inositol levels in symptomatic Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=0032743882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032743882&partnerID=8YFLogxK

M3 - Article

C2 - 10588400

AN - SCOPUS:0032743882

VL - 156

SP - 1879

EP - 1886

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 12

ER -